- Home
- DHY vs MDWD Comparison
DHY vs MDWD Comparison
Compare DHY & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- MDWD
- Stock Information
- Founded
- DHY 1998
- MDWD 2000
- Country
- DHY United States
- MDWD Israel
- Employees
- DHY N/A
- MDWD N/A
- Industry
- DHY Finance/Investors Services
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- DHY Finance
- MDWD Health Care
- Exchange
- DHY Nasdaq
- MDWD Nasdaq
- Market Cap
- DHY 220.7M
- MDWD 208.2M
- IPO Year
- DHY N/A
- MDWD 2014
- Fundamental
- Price
- DHY $2.09
- MDWD $18.10
- Analyst Decision
- DHY
- MDWD Strong Buy
- Analyst Count
- DHY 0
- MDWD 2
- Target Price
- DHY N/A
- MDWD $35.00
- AVG Volume (30 Days)
- DHY 569.1K
- MDWD 70.5K
- Earning Date
- DHY 01-01-0001
- MDWD 08-14-2025
- Dividend Yield
- DHY 9.10%
- MDWD N/A
- EPS Growth
- DHY N/A
- MDWD N/A
- EPS
- DHY N/A
- MDWD N/A
- Revenue
- DHY N/A
- MDWD $19,858,000.00
- Revenue This Year
- DHY N/A
- MDWD $20.64
- Revenue Next Year
- DHY N/A
- MDWD $25.71
- P/E Ratio
- DHY N/A
- MDWD N/A
- Revenue Growth
- DHY N/A
- MDWD N/A
- 52 Week Low
- DHY $1.77
- MDWD $14.14
- 52 Week High
- DHY $2.08
- MDWD $22.51
- Technical
- Relative Strength Index (RSI)
- DHY 38.77
- MDWD 36.05
- Support Level
- DHY $2.11
- MDWD $18.47
- Resistance Level
- DHY $2.14
- MDWD $19.29
- Average True Range (ATR)
- DHY 0.02
- MDWD 0.79
- MACD
- DHY -0.00
- MDWD -0.06
- Stochastic Oscillator
- DHY 0.00
- MDWD 28.03
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.